NEW YORK, Jan. 9, 2017
NEW YORK, Jan. 9, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Agile Therapeutics, Inc. ("Agile" or the "Company") (NASDAQ:AGRX).
The investigation focuses on whether the Company and its executives violated federal securities laws.
Specifically, aftermarket hours on January 3, 2017, the Company released data from its Phase 3 SECURE study evaluating the Company's contraceptive patch, Twirla. Among the results, the Company stated that 51.4% of subjects had withdrawn from the study and that 1.7% of test subjects suffered "serious adverse events." On this news, Agile's share price significantly declined.
Request more information now by clicking here: www.faruqilaw.com/AGRX. There is no cost or obligation to you.
If you invested in Agile stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/AGRX. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Agile's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/agile-notification-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-50000-investing-in-agile-therapeutics-inc-to-contact-the-firm-300388011.html
SOURCE Faruqi & Faruqi, LLP